Octadecyloxyethyl-tenofovir

替诺福韦十八烷氧乙酯

Report date: 2025/03/28 20:01:04
NME

Base Information

Drug NameOctadecyloxyethyl-tenofovir
Drug Alias Name十八烷氧乙基替诺福韦酯ODE-TFV
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInstitute Of Medicinal Of Biotechnology Chinese Academy Of Medical Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXinkai Medicine And Chemical Intermediates (Shanghai) Co LtdInstitute Of Medical Biotechnology, Chinese Academy Of Medical SciencesSuzhou Changzheng-Xinkai Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A